Results 121 to 130 of about 1,333,073 (194)

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 2b Trial of P2X3 Receptor Antagonist Sivopixant for Refractory or Unexplained Chronic Cough. [PDF]

Lung, 2023
McGarvey L, Smith JA, Morice A, Birring SS, Chung KF, Dicpinigaitis PV, Niimi A, Benninger MS, Sher M, Matsunaga Y, Miyazaki S, Machida M, Ishihara H, Mahmood A, Gomez JC.   +14 more
europepmc   +1 more source

Suppression of P2X3 receptor-mediated currents by the activation of α_2A -adrenergic receptors in rat dorsal root ganglion neurons. [PDF]

CNS Neurosci Ther, 2022
Hao JW, Qiao WL, Li Q, Wei S, Liu TT, Qiu CY, Hu WP.   +6 more
europepmc   +1 more source

receptor subunit in mediating multiple sensory effects of ATP

, 2005
Extracellular ATP plays a role in nociceptive signaling and sensory regulation of visceral function through ionotropic receptors variably composed of P2X2 and P2X3 subunits.
Knight, G E, Stephen B. McMahon, Huai‐Zhen Ruan, Yip, P, Philip M. Dunn, Anthony P. D. W. Ford, Dunn, P M, Weifang Rong, Ping Yip, Zhong, Y, Sara G. Hamilton, Nunn, P, Burnstock, G, Debra A. Cockayne, Gillian E. Knight, McMahon, S B, Rong, W, Bei Ma, Geoffrey Burnstock, Ma, B, Philip Nunn, Yu Zhong, Ruan, H Z, Cockayne, D A, Ford, A P, Hamilton, S G   +25 more
core   +1 more source

Synthesis and Structure-Activity Relationship Studies of Benzimidazole-4,7-dione-Based P2X3 Receptor Antagonists as Novel Anti-Nociceptive Agents. [PDF]

Molecules, 2022
Bae J, Kim YO, Han X, Yoon MH, Kim WM, Kim YC.   +5 more
europepmc   +1 more source

Assessment of Pharmacokinetic Interaction Between Gefapixant (MK-7264), a P2X3 Receptor Antagonist, and the OATP1B1 Drug Transporter Substrate Pitavastatin. [PDF]

Clin Pharmacol Drug Dev, 2022
McCrea JB, Hussain A, Ma B, Garrett GC, Evers R, Laabs JE, Stoch SA, Iwamoto M.   +7 more
europepmc   +1 more source

Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial. [PDF]

Pulm Ther, 2022
Smith JA, Kitt MM, Bell A, Noulin N, Tzontcheva A, Seng MM, Lu S.   +6 more
europepmc   +1 more source

Acute P38-Mediated Enhancement of P2X3 Receptor Currents by TNF-α in Rat Dorsal Root Ganglion Neurons. [PDF]

J Inflamm Res, 2021
Jin Y, Wei S, Liu TT, Qiu CY, Hu WP.
europepmc   +1 more source

Eliapixant (BAY 1817080), a P2X3 receptor antagonist, in refractory chronic cough: a randomised, placebo-controlled, crossover phase 2a study. [PDF]

Eur Respir J, 2021
Morice A, Smith JA, McGarvey L, Birring SS, Parker SM, Turner A, Hummel T, Gashaw I, Fels L, Klein S, Francke K, Friedrich C.   +11 more
europepmc   +1 more source

Randomised trial of the P2X₃ receptor antagonist sivopixant for refractory chronic cough. [PDF]

Eur Respir J, 2022
Niimi A, Saito J, Kamei T, Shinkai M, Ishihara H, Machida M, Miyazaki S.   +6 more
europepmc   +1 more source

Inhibition of phosphorylated calcium/calmodulin-dependent protein kinase IIα relieves streptozotocin-induced diabetic neuropathic pain through regulation of P2X3 receptor in dorsal root ganglia. [PDF]

Purinergic Signal, 2023
He XF, Kang YR, Fei XY, Chen LH, Li X, Ma YQ, Hu QQ, Qu SY, Wang HZ, Shao XM, Liu BY, Yi-Liang, Du JY, Fang JQ, Jiang YL.   +14 more
europepmc   +1 more source